NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

PEN

Penumbra Inc

Apr 25 • 04:00PM ET

299.78

Dollar change +1.53
Percentage change 0.51	%

Healthcare • Medical Devices • USA • NYSE

Peers: BSX ISRG EW HOLX MDT JNJ ABT SYK ZBH TFX

| Held by: IJH VTI VB VXF VBK MDY IWP IHI SPMD IJK

Scroll to Statements

Index	-	P/E	281.17	EPS (ttm)	1.07	Insider Own	3.57%	Shs Outstand	38.68M	Perf Week	8.09%
Market Cap	11.61B	Forward P/E	59.33	EPS next Y	5.05	Insider Trans	-11.63%	Shs Float	37.34M	Perf Month	8.95%
Income	42.23M	PEG	6.72	EPS next Q	0.83	Inst Own	90.56%	Short Float	4.20%	Perf Quarter	9.38%
Sales	1.24B	P/S	9.36	EPS this Y	70.90%	Inst Trans	-1.05%	Short Ratio	3.18	Perf Half Y	45.79%
Book/sh	31.35	P/B	9.56	EPS next Y	33.17%	ROA	2.66%	Short Interest	1.57M	Perf Year	45.74%
Cash/sh	9.78	P/C	30.64	EPS next 5Y	41.86%	ROE	3.50%	52W Range	148.00 - 310.00	Perf YTD	26.23%
Dividend Est.	-	P/FCF	77.23	EPS past 5Y	-23.21%	ROI	2.98%	52W High	-3.30%	Beta	0.51
Dividend TTM	-	Quick Ratio	3.68	Sales past 5Y	17.38%	Gross Margin	63.46%	52W Low	102.55%	ATR (14)	12.61
Dividend Ex-Date	-	Current Ratio	6.30	EPS Y/Y TTM	-54.30%	Oper. Margin	9.23%	RSI (14)	65.49	Volatility	4.86% 5.01%
Employees	4500	Debt/Eq	0.18	Sales Y/Y TTM	13.17%	Profit Margin	3.41%	Recom	1.67	Target Price	316.06
Option/Short	Yes / Yes	LT Debt/Eq	0.17	EPS Q/Q	258.58%	Payout	0.00%	Rel Volume	1.23	Prev Close	298.25
Sales Surprise	2.66%	EPS Surprise	24.46%	Sales Q/Q	16.32%	Earnings	Apr 23 AMC	Avg Volume	494.30K	Price	299.78
SMA20	9.47%	SMA50	8.21%	SMA200	28.25%	Trades		Volume	608,522	Change	0.51%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-14-25	Initiated	BofA Securities	Buy	$320
Jan-21-25	Initiated	UBS	Buy	$305
Dec-17-24	Initiated	Oppenheimer	Outperform	$275
Dec-11-24	Upgrade	Wells Fargo	Equal Weight → Overweight	$190 → $275
Sep-18-24	Initiated	Stifel	Buy	$238
Sep-03-24	Initiated	Leerink Partners	Outperform	$263
Jul-31-24	Downgrade	Wells Fargo	Overweight → Equal Weight	$289 → $150
Jul-31-24	Downgrade	Citigroup	Buy → Neutral	$165 → $178
Feb-23-24	Downgrade	JP Morgan	Overweight → Neutral	$284 → $250
Sep-06-23	Initiated	Morgan Stanley	Equal-Weight	$265
Jul-19-23	Initiated	Robert W. Baird	Outperform	$375
Mar-29-23	Downgrade	Needham	Buy → Hold
Jan-30-23	Initiated	Piper Sandler	Overweight	$275
Nov-04-22	Upgrade	Citigroup	Neutral → Buy	$217 → $212
Oct-12-22	Initiated	Jefferies	Buy	$230
Oct-05-22	Downgrade	Citigroup	Buy → Neutral	$170 → $217
Sep-09-22	Upgrade	Needham	Hold → Buy
Jul-18-22	Initiated	RBC Capital Mkts	Outperform	$195
Apr-19-22	Initiated	Deutsche Bank	Buy	$250
Mar-08-22	Initiated	Needham	Hold

Show Previous Ratings

Apr-24-25 10:42AM	Penumbra Q1 Earnings & Revenues Top Estimates, Stock Up, Margins Expand (Zacks) +6.99%
08:10AM	Q1 2025 Penumbra Inc Earnings Call (Thomson Reuters StreetEvents)
03:07AM	Penumbra Inc (PEN) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amidst International ... (GuruFocus.com)
Apr-23-25 08:15PM	Penumbra, Inc. (PEN) Q1 2025 Earnings Call Transcript (Seeking Alpha)
06:00PM	Penumbra (PEN) Reports Q1 Earnings: What Key Metrics Have to Say (Zacks)
05:32PM	Loading…
05:32PM	Penumbra's (NYSE:PEN) Q1 Sales Beat Estimates, Stock Soars (StockStory)
05:15PM	Penumbra (PEN) Q1 Earnings and Revenues Top Estimates (Zacks)
04:17PM	Penumbra: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Penumbra, Inc. Reports First Quarter 2025 Financial Results (PR Newswire)
Apr-22-25 01:04PM	Stroke Management Drug Firm Climbs To Key Level Ahead Of Earnings; But Beware This Pharma Tariff (Investor's Business Daily)
08:04AM	What To Expect From Penumbra's (PEN) Q1 Earnings (StockStory)
Apr-21-25 12:10PM	Why Penumbra (PEN) is Poised to Beat Earnings Estimates Again (Zacks)
Apr-17-25 10:01AM	Integer (ITGR) Earnings Expected to Grow: Should You Buy? (Zacks)
Apr-16-25 10:00AM	Penumbra (PEN) Earnings Expected to Grow: Should You Buy? (Zacks)
Apr-10-25 08:46AM	Tandem Diabetes Care (TNDM) Moves 7.6% Higher: Will This Strength Last? (Zacks)
05:13AM	Loading…
Apr-09-25 05:13AM	3 Reasons PEN is Risky and 1 Stock to Buy Instead (StockStory) +7.68%
Apr-08-25 09:57AM	Reasons to Retain Penumbra Stock in Your Portfolio for Now (Zacks)
Apr-03-25 04:30PM	Penumbra, Inc. Schedules First Quarter 2025 Earnings Release and Conference Call for April 23, 2025 (PR Newswire)
Apr-02-25 09:00AM	Seven New Data Sets Demonstrate Penumbra's Computer Assisted Vacuum Thrombectomy (CAVT) Technology Is Safe, Fast and Effective, Improves Patient Outcomes, and Delivers Healthcare Resource Benefits (PR Newswire)
Mar-28-25 03:59PM	Baird Q4 2024 Small/Mid Cap Growth Equity Commentary (Seeking Alpha)
01:38PM	Baird Q4 2024 Mid Cap Growth Strategy Commentary (Seeking Alpha)
Mar-26-25 11:30AM	Veracyte (VCYT) Up 0.7% Since Last Earnings Report: Can It Continue? (Zacks)
Mar-25-25 03:10PM	Alcon Stock Sees RS Rating Climb To 74 (Investor's Business Daily)
Mar-24-25 11:37AM	New Thrombectomy Product Launches Support PEN Stock Amid Macro Issues (Zacks)
Mar-20-25 11:30AM	Penumbra (PEN) Down 8% Since Last Earnings Report: Can It Rebound? (Zacks)
Mar-15-25 09:40AM	Chipotle upgraded, Charter initiated: Wall Streets top analyst calls (TipRanks)
Mar-04-25 03:04PM	Alcon Stock Gets Relative Strength Rating Lift (Investor's Business Daily)
Feb-28-25 08:01AM	3 Mid-Cap Stocks in Hot Water (StockStory)
Feb-21-25 04:05PM	Penumbra, Inc. Announces Don Kassing will Retire from Board of Directors (PR Newswire)
Feb-20-25 12:00PM	Penumbra (PEN) Upgraded to Buy: Here's Why (Zacks)
04:41PM	Loading…
Feb-19-25 04:41PM	Profit Machine Penumbra Surges On Solid Fourth-Quarter Beat, But Guidance Lags (Investor's Business Daily) +12.03%
01:45PM	Why Penumbra (PEN) Stock Is Trading Up Today (StockStory)
07:46AM	Q4 2024 Penumbra Inc Earnings Call (Thomson Reuters StreetEvents)
02:06AM	Penumbra Inc (PEN) Q4 2024 Earnings Call Highlights: Strong Revenue Growth Amid International ... (GuruFocus.com)
Feb-18-25 06:00PM	Here's What Key Metrics Tell Us About Penumbra (PEN) Q4 Earnings (Zacks)
05:20PM	Penumbra (PEN) Beats Q4 Earnings and Revenue Estimates (Zacks)
04:17PM	Penumbra: Q4 Earnings Snapshot (Associated Press Finance)
04:16PM	Penumbras (NYSE:PEN) Q4 Sales Beat Estimates (StockStory)
04:05PM	Penumbra, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results (PR Newswire)
Feb-17-25 08:06AM	Penumbra (PEN) Reports Q4: Everything You Need To Know Ahead Of Earnings (StockStory)
Feb-14-25 04:04AM	Artivion (NYSE:AORT) Q3 Earnings: Leading The Medical Devices & Supplies - Cardiology, Neurology, Vascular Pack (StockStory)
04:01AM	Unpacking Q3 Earnings: ICU Medical (NASDAQ:ICUI) In The Context Of Other Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks (StockStory)
Feb-13-25 04:02AM	Spotting Winners: Penumbra (NYSE:PEN) And Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks In Q3 (StockStory)
04:01AM	Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks Q3 Teardown: Merit Medical Systems (NASDAQ:MMSI) Vs The Rest (StockStory)
Jan-21-25 04:30PM	Penumbra, Inc. Schedules Fourth Quarter and Full Year 2024 Earnings Release and Conference Call for February 18, 2025 (PR Newswire)
Jan-16-25 12:45PM	3 Reasons Why Growth Investors Shouldn't Overlook Penumbra (PEN) (Zacks)
Jan-08-25 05:06AM	Penumbra (PEN) Surges 6.3%: Is This an Indication of Further Gains? (Zacks)
Dec-30-24 04:30PM	Penumbra, Inc. to Present at the 43rd Annual J.P. Morgan Healthcare Conference (PR Newswire)
Dec-25-24 12:45PM	Is Penumbra (PEN) a Solid Growth Stock? 3 Reasons to Think 'Yes' (Zacks)
Dec-23-24 09:45AM	Here's Why Penumbra (PEN) is a Strong Growth Stock (Zacks)
Dec-19-24 07:37AM	Penumbra price target raised to $285 from $240 at Truist (TipRanks)
Dec-09-24 12:45PM	Penumbra (PEN) is an Incredible Growth Stock: 3 Reasons Why (Zacks)
Dec-06-24 09:45AM	Why Penumbra (PEN) is a Top Growth Stock for the Long-Term (Zacks)
Nov-29-24 11:31AM	Why Is Penumbra (PEN) Up 6.7% Since Last Earnings Report? (Zacks)
Nov-25-24 05:05PM	Penumbra, Inc. (PEN): Innovating in Thrombectomy and Embolization with New FDA-Approved Technologies (Insider Monkey)
Nov-21-24 12:45PM	3 Reasons Growth Investors Will Love Penumbra (PEN) (Zacks)
Nov-20-24 04:30PM	Penumbra, Inc. to Present at the Piper Sandler 36th Annual Healthcare Conference (PR Newswire)
Nov-18-24 10:00AM	Inside a $400 billion bet on the brain-computer interface revolution (Yahoo Finance)
Nov-17-24 04:50PM	Penumbra, Inc. (PEN): A Bull Case Theory (Insider Monkey)
Nov-06-24 12:29PM	Penumbra reveals positive data for algorithm-assisted thrombectomy tech (Clinical Trials Arena)
Nov-05-24 12:45PM	Here is Why Growth Investors Should Buy Penumbra (PEN) Now (Zacks)
09:50AM	Here's Why Penumbra (PEN) is a Strong Momentum Stock (Zacks)
09:00AM	New Late Breaking Data Show Patients Treated with Penumbra's Computer Assisted Vacuum Thrombectomy Technology for Pulmonary Embolism Experience Shorter Hospital Stays and Fewer Complications Compared to Other Treatment Options (PR Newswire)
Nov-04-24 11:19AM	Implied Volatility Surging for Penumbra (PEN) Stock Options (Zacks)
Oct-31-24 03:15AM	Penumbra Inc (PEN) Q3 2024 Earnings Call Highlights: Strong U.S. ... (GuruFocus.com) +8.32%
Oct-30-24 06:30PM	Penumbra (PEN) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
05:30PM	Penumbra (PEN) Q3 Earnings and Revenues Top Estimates (Zacks)
04:24PM	Penumbra: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Penumbra, Inc. Reports Third Quarter 2024 Financial Results (PR Newswire)
Oct-23-24 10:02AM	Penumbra (PEN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
Oct-15-24 10:31AM	Penumbra completes enrolment for THUNDER study to treat ischemic stroke (Medical Device Network)
Oct-14-24 06:20PM	Why Penumbra Stock Zoomed 4% Higher Today (Motley Fool)
09:00AM	Penumbra, Inc. Announces Completion of THUNDER IDE Study Enrollment for Acute Ischemic Stroke (PR Newswire)
Oct-10-24 09:00AM	Get Out the Clot Campaign Brings Together Leaders and Experts to Improve Patient Care for Venous Thromboembolism (PR Newswire)
Oct-09-24 07:50AM	Penumbra price target raised to $222 from $205 at RBC Capital (TipRanks)
Oct-02-24 04:30PM	Penumbra, Inc. Schedules Third Quarter 2024 Earnings Release and Conference Call for October 30, 2024 (PR Newswire)
Sep-18-24 06:29PM	Why Penumbra Stock Zoomed Nearly 5% Higher Today (Motley Fool)
Sep-16-24 06:53AM	Penumbra secures CE mark for CAVT technologies in Europe (Medical Device Network)
03:00AM	Penumbra Receives CE Mark for Computer Assisted Vacuum Thrombectomy Technologies - Lightning Flash 2.0 and Lightning Bolt 7 - in Europe (PR Newswire)
Sep-06-24 01:49AM	Insider Sale: EVP, General Counsel & Secretary Johanna Roberts Sells Shares of Penumbra Inc ... (GuruFocus.com)
01:49AM	Insider Sale: Director Harpreet Grewal Sells Shares of Penumbra Inc (PEN) (GuruFocus.com)
Aug-29-24 11:31AM	Why Is Penumbra (PEN) Up 20% Since Last Earnings Report? (Zacks)
06:55AM	Penumbra axes virtual reality division, will lay off 71 people (MedTech Dive)
Aug-27-24 04:30PM	Penumbra, Inc. to Present at the Baird Global Healthcare Conference (PR Newswire)
Aug-21-24 04:30PM	Penumbra, Inc. to Present at the Wells Fargo Healthcare Conference (PR Newswire)
08:03AM	Penumbra sees 85.5% limb salvage rate in thrombectomy device trial (Medical Device Network)
Aug-16-24 01:01AM	Insider Sale: EVP, General Counsel & Secretary Johanna Roberts Sells Shares of Penumbra Inc ... (GuruFocus.com)
Aug-13-24 07:00AM	Penumbra, Inc. Announces $200 Million Share Repurchase Authorization (PR Newswire) +10.75%
Aug-02-24 04:30PM	Penumbra, Inc. to Present at the Canaccord Genuity Growth Conference (PR Newswire)
Jul-31-24 01:50PM	Q2 2024 Penumbra Inc Earnings Call (Thomson Reuters StreetEvents)
10:03AM	Penumbra (PEN) Tops on Q2 Earnings, Lowers Sales View (Zacks)
Jul-30-24 08:56PM	PEN Stock Earnings: Penumbra Beats EPS, Beats Revenue for Q2 2024 (InvestorPlace)
07:00PM	Penumbra (PEN) Reports Q2 Earnings: What Key Metrics Have to Say (Zacks)
05:30PM	Penumbra (PEN) Q2 Earnings and Revenues Beat Estimates (Zacks)
04:32PM	Penumbra: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Penumbra, Inc. Reports Second Quarter 2024 Financial Results (PR Newswire)
Jul-23-24 10:01AM	Penumbra (PEN) Earnings Expected to Grow: Should You Buy? (Zacks)
Jul-18-24 04:39AM	Penumbra (PEN) Soars 3.3%: Is Further Upside Left in the Stock? (Zacks) -6.11%
Jul-17-24 12:45PM	Looking for a Growth Stock? 3 Reasons Why Penumbra (PEN) is a Solid Choice (Zacks)
Jul-04-24 03:30AM	Insider Sale: EVP, General Counsel & Secretary Johanna Roberts Sells Shares of Penumbra Inc ... (GuruFocus.com)

Penumbra, Inc. is a thrombectomy company, which designs, develops, manufactures, and markets innovative medical products. It offers neurovascular thrombectomy and embolization and access technologies, neurosurgical tools, Penumbra LANTERN Delivery Microcatheter, and Penumbra Occlusion Device system. The company was founded by Arani Bose and Adam Elsesser on June 21, 2004 and is headquartered in Alameda, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Roberts Johanna	EVP, Gen. Counsel & Secretary	Apr 24 '25	Option Exercise	22.04	600	13,224	66,759	Apr 25 07:55 PM
Roberts Johanna	EVP, Gen. Counsel & Secretary	Apr 24 '25	Sale	300.01	600	180,006	66,159	Apr 25 07:55 PM
Elsesser Adam	CEO and President	Apr 16 '25	Option Exercise	30.00	27,976	839,280	80,471	Apr 18 07:38 PM
Elsesser Adam	CEO and President	Apr 16 '25	Sale	274.35	16,560	4,543,228	63,911	Apr 18 07:38 PM
O'Rourke Bridget	Director	Apr 15 '25	Sale	271.21	50	13,560	5,523	Apr 17 07:34 PM
ADAM ELSESSER	Officer	Apr 16 '25	Proposed Sale	274.35	16,560	4,543,181		Apr 16 04:41 PM
Elsesser Adam	CEO and President	Apr 02 '25	Option Exercise	30.00	41,308	1,239,240	69,060	Apr 04 08:38 PM
Elsesser Adam	CEO and President	Apr 02 '25	Sale	272.24	16,565	4,509,728	52,495	Apr 04 08:38 PM
Wilder Thomas	Director	Apr 02 '25	Sale	266.93	360	96,095	4,692	Apr 04 08:36 PM
Wilder Thomas	Director	Mar 31 '25	Sale	264.58	360	95,249	4,533	Apr 02 07:34 PM
Roberts Johanna	EVP, Gen. Counsel & Secretary	Apr 01 '25	Option Exercise	22.04	600	13,224	66,953	Apr 02 07:33 PM
Roberts Johanna	EVP, Gen. Counsel & Secretary	Apr 01 '25	Sale	269.11	600	161,466	66,353	Apr 02 07:33 PM
Grewal Harpreet	Director	Apr 01 '25	Sale	267.17	200	53,434	9,074	Apr 02 07:33 PM
THOMAS AND CATHARINE WILDER FA	Director	Apr 02 '25	Proposed Sale	266.93	360	96,095		Apr 02 04:04 PM
ADAM ELSESSER	Officer	Apr 02 '25	Proposed Sale	272.24	16,565	4,509,702		Apr 02 04:02 PM
Grewal Harpreet	Director	Apr 01 '25	Proposed Sale	267.17	200	53,434		Apr 01 04:07 PM
DON W KASSING	Director	Apr 01 '25	Proposed Sale	267.17	166	44,350		Apr 01 04:06 PM
THOMAS AND CATHARINE WILDER FA	Director	Mar 31 '25	Proposed Sale	264.58	360	95,249		Mar 31 04:03 PM
Bose Arani	Director	Mar 25 '25	Sale	283.77	12,000	3,405,253	314,819	Mar 27 08:01 PM
Elsesser Adam	CEO and President	Mar 19 '25	Option Exercise	30.00	27,976	839,280	44,352	Mar 21 07:32 PM
Elsesser Adam	CEO and President	Mar 19 '25	Sale	276.21	16,600	4,585,138	27,752	Mar 21 07:32 PM
ADAM ELSESSER	Officer	Mar 19 '25	Proposed Sale	276.21	16,600	4,585,104		Mar 19 04:27 PM
Elsesser Adam	CEO and President	Mar 05 '25	Option Exercise	30.00	72,976	2,189,280	77,976	Mar 07 08:03 PM
Elsesser Adam	CEO and President	Mar 05 '25	Sale	283.59	61,600	17,468,917	16,376	Mar 07 08:03 PM
Roberts Johanna	EVP, Gen. Counsel & Secretary	Mar 03 '25	Option Exercise	22.04	600	13,224	67,139	Mar 05 07:37 PM
Roberts Johanna	EVP, Gen. Counsel & Secretary	Mar 03 '25	Sale	287.43	600	172,458	66,539	Mar 05 07:37 PM
O'Rourke Bridget	Director	Mar 03 '25	Sale	285.48	50	14,274	5,573	Mar 05 07:36 PM
Bose Arani	Director	Mar 03 '25	Sale	287.42	12,000	3,448,993	326,819	Mar 05 07:35 PM
Yuen Maggie	Chief Financial Officer	Mar 05 '25	Option Exercise	158.30	900	142,470	16,143	Mar 05 07:35 PM
Yuen Maggie	Chief Financial Officer	Mar 03 '25	Sale	286.00	2,000	571,995	15,243	Mar 05 07:35 PM
Shiu Lambert	Chief Accounting Officer	Mar 04 '25	Option Exercise	22.04	9,200	202,768	33,470	Mar 05 07:35 PM
Shiu Lambert	Chief Accounting Officer	Mar 03 '25	Sale	285.93	7,288	2,083,860	24,270	Mar 05 07:35 PM
Shiu Lambert	Chief Accounting Officer	Mar 04 '25	Sale	282.88	501	141,723	32,969	Mar 05 07:35 PM
ADAM ELSESSER	Officer	Mar 05 '25	Proposed Sale	283.59	61,600	17,468,975		Mar 05 04:27 PM
LAMBERT SHIU	Officer	Mar 04 '25	Proposed Sale	282.88	501	141,723		Mar 04 05:10 PM
Arani Bose	Affiliate	Mar 03 '25	Proposed Sale	285.44	48,000	13,701,120		Mar 03 04:47 PM
MAGGIE YUEN	Officer	Mar 03 '25	Proposed Sale	286.00	2,000	571,995		Mar 03 04:39 PM
LAMBERT SHIU	Officer	Mar 03 '25	Proposed Sale	285.93	7,288	2,083,853		Mar 03 04:36 PM
Johanna Roberts	Officer	Mar 03 '25	Proposed Sale	285.54	3,600	1,027,949		Mar 03 04:28 PM
Shiu Lambert	Chief Accounting Officer	Feb 14 '25	Option Exercise	22.04	4,525	99,731	29,503	Feb 19 07:39 PM
Grewal Harpreet	Director	Jan 03 '25	Sale	241.28	167	40,294	8,530	Jan 06 08:03 PM
Kassing Don W.	Director	Jan 02 '25	Sale	238.84	170	40,603	665	Jan 06 08:03 PM
Grewal Harpreet	Director	Jan 03 '25	Proposed Sale	241.28	167	40,294		Jan 03 03:50 PM
Roberts Johanna	EVP, Gen. Counsel & Secretary	Dec 26 '24	Option Exercise	22.04	1,350	29,754	64,000	Dec 27 08:02 PM
Elsesser Adam	CEO and President	Dec 20 '24	Sale	242.96	15,000	3,644,438	837,582	Dec 23 07:37 PM
Roberts Johanna	EVP, Gen. Counsel & Secretary	Dec 02 '24	Sale	244.49	600	146,697	63,444	Dec 03 08:27 PM
Shiu Lambert	Chief Accounting Officer	Dec 03 '24	Option Exercise	12.36	5,250	64,890	25,278	Dec 03 08:27 PM
Shiu Lambert	Chief Accounting Officer	Nov 29 '24	Sale	242.56	1,798	436,123	20,682	Dec 03 08:27 PM
Shiu Lambert	Chief Accounting Officer	Dec 02 '24	Sale	243.01	654	158,929	20,028	Dec 03 08:27 PM
LAMBERT SHIU	Officer	Dec 02 '24	Proposed Sale	243.01	654	158,929		Dec 02 04:05 PM
LAMBERT SHIU	Officer	Nov 29 '24	Proposed Sale	242.56	1,798	436,123		Nov 29 01:28 PM
Elsesser Adam	CEO and President	Nov 20 '24	Sale	237.28	15,000	3,559,176	852,582	Nov 22 08:38 PM
Adam Elsesser	Affiliate	Nov 20 '24	Proposed Sale	237.11	30,000	7,113,300		Nov 20 05:42 PM
Roberts Johanna	EVP, Gen. Counsel & Secretary	Nov 18 '24	Sale	239.74	600	143,843	64,044	Nov 19 08:04 PM
Elsesser Adam	CEO and President	Oct 21 '24	Sale	204.56	15,000	3,068,367	867,582	Oct 23 07:31 PM
Grewal Harpreet	Director	Oct 02 '24	Sale	190.83	166	31,678	8,697	Oct 03 07:33 PM
Roberts Johanna	EVP, Gen. Counsel & Secretary	Oct 01 '24	Sale	190.76	600	114,456	60,488	Oct 03 07:32 PM
Kassing Don W.	Director	Oct 01 '24	Sale	193.93	170	32,968	835	Oct 03 07:32 PM
Grewal Harpreet	Director	Oct 02 '24	Proposed Sale	190.83	166	31,678		Oct 02 04:00 PM
Elsesser Adam	CEO and President	Sep 20 '24	Sale	197.71	15,000	2,965,646	882,582	Sep 24 07:29 PM
Roberts Johanna	EVP, Gen. Counsel & Secretary	Sep 03 '24	Sale	206.22	600	123,733	61,088	Sep 05 07:48 PM
Grewal Harpreet	Director	Sep 04 '24	Sale	204.11	782	159,614	8,863	Sep 05 07:48 PM
Grewal Harpreet	Director	Sep 04 '24	Proposed Sale	204.11	782	159,614		Sep 04 04:13 PM
Johanna Roberts	Officer	Sep 03 '24	Proposed Sale	202.32	2,400	485,568		Sep 03 07:02 PM
Elsesser Adam	CEO and President	Aug 23 '24	Sale	203.37	28,380	5,771,597	897,582	Aug 26 07:46 PM
Elsesser Adam	CEO and President	Aug 22 '24	Sale	200.00	1,620	324,000	925,962	Aug 26 07:46 PM
Adam Elsesser	Affiliate	Aug 22 '24	Proposed Sale	195.21	60,000	11,712,600		Aug 22 04:49 PM
Roberts Johanna	EVP, Gen. Counsel & Secretary	Aug 13 '24	Sale	175.98	600	105,587	61,688	Aug 15 07:41 PM
Elsesser Adam	CEO and President	Jul 17 '24	Sale	202.52	15,000	3,037,744	927,582	Jul 19 07:31 PM
Kassing Don W.	Director	Jul 01 '24	Sale	179.99	170	30,598	1,005	Jul 03 08:02 PM
Roberts Johanna	EVP, Gen. Counsel & Secretary	Jul 01 '24	Sale	179.20	600	107,519	62,288	Jul 03 08:01 PM
Roberts Johanna	EVP, Gen. Counsel & Secretary	Jun 03 '24	Sale	188.90	600	113,339	62,888	Jun 05 07:31 PM
Elsesser Adam	CEO and President	May 20 '24	Sale	200.98	15,000	3,014,734	942,582	May 22 07:38 PM
Roberts Johanna	EVP, Gen. Counsel & Secretary	May 13 '24	Sale	207.41	600	124,447	63,488	May 15 07:34 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PEN

Penumbra Inc

Upgrade your FINVIZ experience